Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine.

McCall, Anthony L; Cox, Daniel J; Brodows, Robert; Crean, John; Johns, Don; Kovatchev, Boris

McCall, Anthony L; Cox, Daniel J; Brodows, Robert; Crean, John; Johns, Don; Kovatchev, Boris.

Affiliation

McCall AL; University of Virginia Health System, Charlottesville, Virginia 22908, USA. alm3j@virginia.edu

Diabetes Technol Ther ; 11(6): 339-44, 2009 Jun.

Article in En | MEDLINE | ID: mdl-19459761

Subject(s)

Blood Glucose/drug effects; Diabetes Mellitus, Type 2/drug therapy; Hypoglycemic Agents/therapeutic use; Insulin/analogs & derivatives; Peptides/therapeutic use; Venoms/therapeutic use; Adult; Aged; Blood Glucose/metabolism; Diabetes Mellitus, Type 2/blood; Exenatide; Humans; Insulin/therapeutic use; Insulin Glargine; Insulin, Long-Acting; Metformin/therapeutic use; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Sulfonylurea Compounds/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptides / Venoms / Blood Glucose / Diabetes Mellitus, Type 2 / Hypoglycemic Agents / Insulin Type of study: Clinical_trials / Etiology_studies Limits: Adult / Aged / Humans / Middle aged Language: En Journal: Diabetes Technol Ther Journal subject: ENDOCRINOLOGIA / TERAPEUTICA Year: 2009 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google